Gilead shares made a slight gain early on Monday after the firm announced that there would be a big change at the top, in terms of its senior management. Not to mention,…
Chris Lange The November 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The October 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Gilead shares retreated on Friday after it reported mixed third-quarter financial results late on Thursday.
Chris Lange The top analyst upgrades, downgrades and other research calls from Friday included GoldCorp, Gilead, GrubHub, Hilton Worldwide, KKR, Raymond James and Western Digital.
The October 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming week.
The September 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The September 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own.…
Jon C. Ogg Jefferies highlights the firm's top growth stocks to buy each week, and recently four top biotech stocks made the cut. They all make good sense now, and all have outstanding upside potential.
Lee Jackson 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data have been compared with the previous report, and short interest in most…
Gilead shares were up handily on Wednesday after the company announced that it had entered into a strategic collaboration with Precision BioSciences.
Chris Lange The topic of acceptable costs versus acceptable results is one that may never have a final conclusion in which everyone agrees.
The August 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
